Correlation Between Day One and Virax Biolabs

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Day One and Virax Biolabs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Day One and Virax Biolabs into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Day One Biopharmaceuticals and Virax Biolabs Group, you can compare the effects of market volatilities on Day One and Virax Biolabs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Day One with a short position of Virax Biolabs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Day One and Virax Biolabs.

Diversification Opportunities for Day One and Virax Biolabs

0.06
  Correlation Coefficient

Significant diversification

The 3 months correlation between Day and Virax is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Day One Biopharmaceuticals and Virax Biolabs Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virax Biolabs Group and Day One is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Day One Biopharmaceuticals are associated (or correlated) with Virax Biolabs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virax Biolabs Group has no effect on the direction of Day One i.e., Day One and Virax Biolabs go up and down completely randomly.

Pair Corralation between Day One and Virax Biolabs

Given the investment horizon of 90 days Day One Biopharmaceuticals is expected to under-perform the Virax Biolabs. But the stock apears to be less risky and, when comparing its historical volatility, Day One Biopharmaceuticals is 3.1 times less risky than Virax Biolabs. The stock trades about -0.02 of its potential returns per unit of risk. The Virax Biolabs Group is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  783.00  in Virax Biolabs Group on December 4, 2024 and sell it today you would lose (636.00) from holding Virax Biolabs Group or give up 81.23% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Day One Biopharmaceuticals  vs.  Virax Biolabs Group

 Performance 
       Timeline  
Day One Biopharmaceu 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Day One Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Virax Biolabs Group 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Virax Biolabs Group are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Virax Biolabs may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Day One and Virax Biolabs Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Day One and Virax Biolabs

The main advantage of trading using opposite Day One and Virax Biolabs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Day One position performs unexpectedly, Virax Biolabs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virax Biolabs will offset losses from the drop in Virax Biolabs' long position.
The idea behind Day One Biopharmaceuticals and Virax Biolabs Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities